Cargando…
Successful Discontinuation of Eculizumab in a Pediatric Patient With Atypical Hemolytic Uremic Syndrome and Underlying Systematic Lupus Erythematosus
Although rare, atypical hemolytic syndrome (aHUS) has been recognized as one of the direst complications of systemic lupus erythematosus (SLE). Furthermore, the diagnosis of coexisting aHUS and SLE is a diagnostic dilemma with similar clinical characteristics between both entities. Eculizumab is an...
Autores principales: | Alhamoud, Issa, Freiberg, Sydney A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205680/ https://www.ncbi.nlm.nih.gov/pubmed/35733457 http://dx.doi.org/10.7759/cureus.25117 |
Ejemplares similares
-
Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017) -
Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis,
Responsive to Eculizumab
por: Raufi, Alexander G., et al.
Publicado: (2016) -
Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome
por: Ranabothu, Saritha, et al.
Publicado: (2021) -
A Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
por: Thajudeen, B., et al.
Publicado: (2013) -
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
por: AlZabali, Saeed, et al.
Publicado: (2022)